Sacubitril/Valsartan for CKD5 Stage Dialysis Patients
Phase 4
Completed
- Conditions
- CKD5 Stage DialysisHeart Failure
- Interventions
- First Posted Date
- 2022-02-16
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 330
- Registration Number
- NCT05243199
- Locations
- 🇨🇳
Department of Nephrology, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, Shanghai, China
Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis
Phase 2
- Conditions
- Gastric Cancer Stage IVPeritoneal Metastases
- Interventions
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05204173
- Locations
- 🇨🇳
Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Irinotecan And Bevacizumab Combined With Re-radiotherapy in Recurrent Glioblastoma
Phase 1
Recruiting
- Conditions
- Recurrent Glioblastoma
- Interventions
- Drug: Bevacizumab，Irinotecan and Re-radiotherapy
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05201326
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Influence Factors of PD-1 Therapeutic Efficacy in Advanced Pancreatic Cancer
- Conditions
- Pancreatic Ductal Adenocarcinoma, PDAC
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05201729
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
Chinese FMDs Registry
- Conditions
- Functional Movement Disorders
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05201521
- Locations
- 🇨🇳
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Retrospective Study on Microbial Diversity in Paraffin Tissue of Pancreatic Diseases
Recruiting
- Conditions
- Pancreatic DiseasePancreatic CancerMicrobial Colonization
- Interventions
- Other: No any intervention
- First Posted Date
- 2022-01-14
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 800
- Registration Number
- NCT05193162
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, China
Mechanism of Resistance to GNC-038 in Relapsed and Refractory Diffuse Large B-cell Lymphoma
Recruiting
- Conditions
- Diffuse Large B Cell Lymphoma
- First Posted Date
- 2022-01-13
- Last Posted Date
- 2022-08-31
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT05189782
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
SHR6390 Plus Nab-paclitaxel and Gemcitabine in Advanced/Metastatic Pancreatic Cancer
Phase 2
Not yet recruiting
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 58
- Registration Number
- NCT05185869
- Locations
- 🇨🇳
Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years
Phase 3
Recruiting
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- Drug: six courses of zanubrutinib, rituximab and lenalidomideDrug: six courses of rituximab combined with low-dose CHOP
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2023-05-23
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 280
- Registration Number
- NCT05179733
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
Lenvatinib With Taxane Drugs Treatment for Advanced Gastric Cancer
Phase 1
- Conditions
- HER2-negative Advanced Gastric Cancer
- Interventions
- First Posted Date
- 2021-12-29
- Last Posted Date
- 2021-12-29
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT05171530
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath